source
- Viking Therapeutics reports obesity drug maintains weight loss after dosing switch, shares jump 36%Viking Therapeutics said its Phase 2 trial of the dual-acting obesity candidate VK2735 showed participants largely kept the weight they had lost when the dosing schedule changed from a weekly injec…
- Trump administration’s MFN drug pricing deals may cut projected Medicare savings by up to 80%The White House announced "most-favored-nation" pricing agreements with 26 pharmaceutical companies, saying the contracts would lower drug costs for federal programs. The deals require companies to…